Abstract: Chromatographic method for separation of AAV capsid proteins using hydrophilic-interaction chromatography (HILIC). The method provides the ability to quantify capsid protein ratio and to separate capsid proteins to the extent that low level post-translational modifications (PTMs) can be detected by mass spectrometry.
Type:
Application
Filed:
December 13, 2021
Publication date:
February 15, 2024
Applicant:
Pfizer Inc.
Inventors:
Mark Thomas Chipley, Thomas Wesley Powers
Abstract: The present invention relates to a method of identifying a metastatic tumor determined to have a mutation in homologous recombination pathway genes, that is sensitive to treatment with talazoparib, or a pharmaceutically acceptable salt thereof, and methods of treatment thereof, comprising a) determining a homologous recombination deficiency score from a biopsy of the metastatic tumor; and b) administering talazoparib, or a pharmaceutically acceptable salt thereof, if the homologous recombination deficiency score is at least 33%, wherein the mutation is not germline BRCA1 or germline BRCA2. The present invention also relates to a method of selecting a subject determined to have a metastatic tumor with a mutation in homologous recombination pathway genes, for treatment with talazoparib, or a pharmaceutically acceptable salt thereof.
Abstract: Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
February 13, 2024
Assignees:
Bristol-Myers Squibb Company, Pfizer Inc.
Inventors:
Sherif Ibrahim Farag Badawy, Timothy D. Stevens, Daniel Kuntz, Brett Waybrant
Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Type:
Grant
Filed:
October 6, 2021
Date of Patent:
February 6, 2024
Assignee:
Pfizer Inc.
Inventors:
Eric Christian Hansen, Christopher Scott Seadeek, Anil Mahadeo Rane
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Type:
Application
Filed:
September 28, 2023
Publication date:
February 1, 2024
Applicant:
Pfizer Inc.
Inventors:
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Type:
Grant
Filed:
July 28, 2023
Date of Patent:
January 30, 2024
Assignee:
PFIZER INC.
Inventors:
Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Type:
Grant
Filed:
November 21, 2022
Date of Patent:
January 30, 2024
Assignee:
PFIZER INC.
Inventors:
Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Abstract: The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.
Type:
Grant
Filed:
November 30, 2020
Date of Patent:
January 30, 2024
Assignee:
Pfizer Inc.
Inventors:
Fabio Cataldi, Robert A. Clare, Gail M. Comer, Vivekananda Pradhan, Alaa Ahmad, Mina Hassan-Zahraee, Mera Krishnan Tilley, Weidong Zhang, Anindita Banerjee, Karen Michelle Page, Michael Steven Vincent, David J. Von Schack
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
Type:
Application
Filed:
August 25, 2023
Publication date:
January 18, 2024
Applicant:
PFIZER INC.
Inventors:
Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
Abstract: The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.
Type:
Application
Filed:
August 15, 2023
Publication date:
January 18, 2024
Applicant:
Pfizer Inc.
Inventors:
James Reasoner Apgar, Andrea Therese Hooper, Malgorzata Agnieszka Nocula-Lugowska, Lei Wu
Abstract: The invention relates to methods for producing an RSV F protein trimer in a fed batch cell culture.
Type:
Application
Filed:
September 30, 2021
Publication date:
January 18, 2024
Applicant:
Pfizer Inc.
Inventors:
Shelby Hutchins BREEN, Cameron Albert HARRINGTON, Michaela Evelina JACOBS, Jason Arnold LOTVIN, Bhanu Chandra MULUKUTLA, David STEAD, Madhuresh SUMIT
Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRP?Fc is enhanced in the presence of daratumumab. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
Type:
Application
Filed:
August 30, 2023
Publication date:
January 18, 2024
Applicant:
Pfizer Inc.
Inventors:
Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Jeffrey Todd WINSTON, Robert Adam UGER
Abstract: An injector, comprising a housing arranged along a longitudinal axis and configured to receive a medicament cartridge; an injection drive mechanism for driving a piston, the piston forming part of the medicament cartridge, the injection drive mechanism injecting a medicament when the piston is forwardly displaced; and a needle hiding element, which is slidably attached to the housing and positionable in at least one of an extended orientation and a retracted orientation, wherein in the extended orientation the needle hiding element protrudes forwardly from the housing and in the retracted orientation, the needle hiding element is locked relative to the housing.
Type:
Application
Filed:
November 12, 2021
Publication date:
January 18, 2024
Applicant:
PFIZER, INC.
Inventors:
Ilan KACHLER, Idan NAAMAN, Amotz PORAT, Tom SHEFER
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
Type:
Grant
Filed:
March 6, 2021
Date of Patent:
January 16, 2024
Assignee:
Pfizer Inc.
Inventors:
Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-Ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
Abstract: IL-12 variants are provided. Also provided are antibodies that specifically bind to PD1. Also provided are fusion proteins of IL-12 variants and anti-PD1 antibodies. Also provided are uses of these IL-12 variants, anti-PD1 antibodies, fusion proteins, and related compositions and methods.
Type:
Application
Filed:
June 15, 2023
Publication date:
January 11, 2024
Applicant:
Pfizer Inc.
Inventors:
James Reasoner APGAR, Javier Fernando CHAPARRO RIGGERS, Ling Hon Matthew CHU, Tzu-Hsuan HUANG, Kritika MOHAN, Lidia MOSYAK, Edward Derrick PASCUA, James Travis PATTERSON, Gabriel Roy STARBECK-MILLER, Dirk Michael ZAJONC
Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
Type:
Application
Filed:
June 2, 2023
Publication date:
January 11, 2024
Applicants:
Debiopharm International S.A., Merck Patent GmbH, Pfizer Inc.
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
January 9, 2024
Assignee:
Pfizer Inc.
Inventors:
Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li